Has Mark Meadows, MD received payments from drug or device companies?

Yes. Drug and device makers reported $160 in general payments to Mark Meadows, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Meadows, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Meadows, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Meadows, MD

Ophthalmology · Baton Rouge, LANPI 1538178751

Payments from drug & device makers

$160in general payments, 2019–2025

Across 8 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$53
Glaukos Corporation$43
Johnson & Johnson Surgical Vision, Inc.$32
Kala Pharmaceuticals, Inc.$19
Heidelberg Engineering, Inc.$13

What the payments were for

Food & beverage$160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	3	$53
Glaukos Corporation	2	$43
Johnson & Johnson Surgical Vision, Inc.	1	$32
Kala Pharmaceuticals, Inc.	1	$19
Heidelberg Engineering, Inc.	1	$13

How this compares

$160 in reported general payments places this provider in the 10th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$166,209

Medicare patients

291

Services billed

979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Latanoprost	860	$6,060
Prednisolone Acetate	163	$5,547
Travoprost	33	$3,317
Timolol Maleate	314	$2,838
Brimonidine Tartrate	331	$2,286
Dorzolamide Hcl	109	$1,852
Acetazolamide	27	$1,756
Flurbiprofen Sodium	56	$1,689
Ciprofloxacin Hcl	117	$1,412
Ketorolac Tromethamine	42	$1,035
Fluorometholone	13	$885
Tobramycin-DexamethasoneTobramycin/Dexamethasone	11	$573
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	18	$242

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Baton Rouge

Blake WilliamsonBaton Rouge$482K
Thomas StuckeyBaton Rouge$28K
Charles WilliamsonBaton Rouge$16K
David FargasonBaton Rouge$6K
Philip EhrlichBaton Rouge$6K
Daniel NelsonBaton Rouge$6K
Michael MorganBaton Rouge$6K
George FivgasBaton Rouge$6K
William ReadMonroe$303K
Delmar CaldwellNew Orleans$282K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →